The average lifetime risk of pancreatic cancer is reported to be around 1 in 60 in women and 1 in 56 in men. In the United States, nearly 3% of cancers are pancreatic cancer and are responsible for approximately 7% of all cancer deaths. Advanced pancreatic cancer is usually stage III or IV pancreatic cancer. It occurs when the cancer spreads beyond the pancreas to the other parts of the body and can't be removed by surgery. Current therapies offer only modest survival benefits and are associated with significant toxicity. Thus, there is a critical need for safe and effective targeted therapies and immunotherapies that can combat the aggressive nature of this disease.
The Advanced Pancreatic Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into advanced pancreatic cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced pancreatic cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced pancreatic cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced pancreatic cancer.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced pancreatic cancer.
Advanced pancreatic cancer spreads extensively within the pancreas (locally advanced) or to other parts of the body (metastatic pancreatic cancer). Pancreatic cancer is often diagnosed at an advanced stage as the symptoms are not evident in its early stages. Common symptoms include unexplained weight loss, abdominal pain, vomiting, jaundice, and digestive problems, among others.
Advanced pancreatic cancer is a challenging condition to treat owing to its late diagnosis, aggressive progression, and resistance to standard therapies. Moreover, complex tumor biology makes it difficult for drugs to penetrate tumors effectively. The rising focus on new biomarker research and mRNA-based vaccines is anticipated to improve patient outcomes in the coming years. Additionally, the growing advancements in immunotherapy and robust regulatory support are poised to positively impact the drug pipeline landscape for advanced pancreatic cancer in the near future.
This section of the report covers the analysis of advanced pancreatic cancer drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for advanced pancreatic cancer.
The drug molecule categories covered under the advanced pancreatic cancer pipeline analysis include small molecules, monoclonal antibodies, gene therapies, oncolytic viruses, and immunotherapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced pancreatic cancer.
The EMR report for the advanced pancreatic cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced pancreatic cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by the National Cancer Institute (NCI), the primary objective of this Phase II single cohort clinical trial with one arm is to evaluate the antitumor activity of the drug candidate minnelide in an estimated 55 adults aged 18 and older with advanced refractory adenosquamous carcinoma of the pancreas (ASCP).
HCW Biologics is conducting a Phase Ib/II clinical trial aimed at investigating the safety and efficacy of HCW...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Advanced Pancreatic Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced pancreatic cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced pancreatic cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share